Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.64 |
| ▸ | BLM | P54132 | 9/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 2/20 | 0.41 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | WRN | Q14191 | 3/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201770 | 0.95 | BRAF (0.58) | BRAFBLMMCL1CCNCCDK8 | |
| SCHEMBL4203385 | 0.89 | BRAF (0.65) | BRAFBLMCNR1WRN | |
| SCHEMBL4195857 | 0.88 | BRAF (0.66) | BRAFBLMMCL1CNR1KDM4E | |
| SCHEMBL3976693 | 0.85 | BRAF (0.83) | BRAFBLMCDK8RAB9AMEN1 | |
| SCHEMBL4199761 | 0.84 | BRAF (0.69) | BRAFBLMCDK8CNR1WRN | |
| SCHEMBL4198711 | 0.83 | BRAF (0.59) | BRAFCNR1RAB9AMEN1MAPT | |
| SCHEMBL4205760 | 0.83 | BRAF (0.68) | BRAFBLMCDK8WRNKDR | |
| SCHEMBL4204275 | 0.82 | BRAF (0.59) | BRAFMCL1CNR1KDM4ERAB9A | |
| SCHEMBL4194851 | 0.80 | BRAF (0.75) | BRAFMEN1MAPTKMT2AKDR | |
| SCHEMBL4196576 | 0.80 | BRAF (0.78) | BRAFMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | BRAF, ARAF, RAF1 | BRAF 1/4885BLM 2054/4885MCL1 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.